● Recruiting

A Randomized, Double-blind, Placebo-controlled, Single and Multiple Dose Escalation Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IMC-003 for Injection in Healthy Postmenopausal Women

Condition: Healthy Postmenopausal Women · Sponsor: ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

PhasePhase 1

Planned participants56

Who can joinFemale, 45 Years to 75 Years

Healthy volunteersYes

About this study

this study is a randomized, double-blind, placebo-controlled, single and multiple dose escalation Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of IMC-003 for injection in healthy postmenopausal women.

This description comes directly from the study's public registry record.

Talk to the study team

Chunyan Yuan, Bachelor · 0086-18621599098 · chunyan.yuan@immunecarebio.com

Always discuss trial participation with your own doctor first.

Locations (1)

Chengdu Xinhua hospital

Chengdu, Sichuan, China

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07118085